Health Care • Biotechnology: Commercial Physical & Biological Resarch
$652.01 ▼ -25.55
(-3.77%)
MKT CAP: $18.95B • VOL: 219.6K
52W L $373 52W H $694
MEDP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.53B | $2.11B | $1.89B |
| YoY Revenue Growth % | +20.0% | +11.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $534.9M | $446.9M | $336.8M |
| Operating Margin % | 21.1% | 21.2% | 17.9% |
| Net Income (GAAP) | $451.1M | $404.4M | $282.8M |
| EBITDA (Normalized) | $560.0M | $476.1M | $404.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $713.2M | $608.8M | $433.4M |
| Capital Expenditures (CapEx) | $31.4M | $36.5M | $84.9M |
| Free Cash Flow (FCF) | $681.9M | $572.3M | $348.5M |
| FCF Margin % | 26.9% | 27.1% | 18.5% |
| Return on Invested Capital (ROIC %) | 65.6% | 48.4% | 4.2% |
| Cash & Short-Term Equivalents | $497.0M | $669.4M | — |
| Total Debt (Short + Long Term) | $682.4M | $573.9M | $2.44B |
| Total Stockholders' Equity | $459.1M | $825.5M | $5.00B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MEDP.